BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ACMELAB

All Eps Dividend Board Agm Q1 Q2 Q3

ACMELAB 13-Jun-2019

The Company has informed that the Board of Directors has declared the commencement of Commercial Production of its state of the art Penicillin facility at Dulivita, Dhamrai, Dhaka after successful completion of trial production. The Company noted that the aforesaid Penicillin facility is one of the three projects against which fund was raised through Initial Public Offering (IPO).

ACMELAB 29-Apr-2019

(Q3 Un-audited): EPS was Tk. 1.74 for January-March 2019 as against Tk. 1.85 for January-March 2018; EPS was Tk. 5.43 for July 2018-March 2019 as against Tk. 5.66 for July 2017-March 2018. NOCFPS was Tk. 5.15 for July 2018-March 2019 as against Tk. 6.80 for July 2017-March 2018. NAV per share was Tk. 85.32 as on March 31, 2019 and Tk. 83.39 as on June 30, 2018.

ACMELAB 24-Apr-2019

The Company has informed that Mr. Afzalur Rahman Sinha, one of the Directors of the Company passed away on 08.08.2018. His total holding of 1,72,14,336 shares have already been transmitted in the accounts of his nominees namely Mr. Fahim Sinha (son) and Mrs. Sabrina Juned (daughter) by way of nomination at 50:50 ratio.

ACMELAB 24-Apr-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2019 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2019.

ACMELAB 11-Mar-2019

The Company has informed that they have received the certificate of GMP Compliance from UK MHRA (Medicines and Healthcare Products Regulatory Agency of UK) following successful inspection of its Solid Dosage Unit (SDU) at Dhulivita, Dhamrai, Dhaka -1350, Bangladesh. This success will open the doors for the company to enter UK and other European Markets.

ACMELAB 31-Jan-2019

(Q2 Un-audited): EPS was Tk. 1.85 for October-December, 2018 as against Tk. 1.82 for October-December, 2017; EPS was Tk. 3.69 for July-December, 2018 as against Tk. 3.81 for July-December, 2017. NOCFPS was Tk. 4.61 for July-December, 2018 as against Tk. 6.09 for July-December, 2017. NAV per share was Tk. 83.56 as on December 31, 2018 and Tk. 83.39 as on June 30, 2018.

ACMELAB 28-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

ACMELAB 06-Jan-2019

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2018 to the respective shareholders' Bank Accounts through BEFTN system.

ACMELAB 24-Dec-2018

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA-" in the long term and "ST-3 " in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2018; un-audited financials up to September 30, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ACMELAB 14-Nov-2018

(Q1 Un-audited): EPS was Tk. 1.84 for July-September, 2018 as against Tk. 1.99 for July-September, 2017; NOCFPS was Tk. 2.35 for July-September, 2018 as against Tk. 3.61 for July-September, 2017. NAV per share was Tk. 85.21 as on September 30, 2018 and Tk. 83.39 as of June 30, 2018.

Previous Next page